| Today, Québec Science named the cancer vaccine developed by Dr. Claude Perreault’s team at the Université de Montréal’s Institute for Research in Immunology and Cancer (IRIC) the Discovery of the Year. Oncopole proudly acknowledges the exceptional work of Dr. Perreault’s team, which it has supported for many years. Recipient of a $2.3 million grant through the EMC2 program, the Perreault laboratory has been able to hone its knowledge of the development of a potential vaccine against ovarian cancer in particular. As a proud partner in this adventure, Oncopole congratulates Dr. Perreault, Sébastien Lemieux and Pierre Thibault for their commitment and contribution to the advancement of knowledge in the development of a therapeutic cancer vaccine.
“I would like to congratulate Dr. Perreault on his exceptional work and intellectual curiosity. Oncopole’s role is to fund promising projects led by talented researchers. The entire Oncopole team joins me in warmly thanking Dr. Claude Perrault and his collaborators for the hope generated by their research! Their project has now been recognized by both the general public and the scientific community,” emphasizes Renaldo Battista, General Manager of Oncopole.
The health crisis caused by the COVID-19 pandemic shows us just how crucial scientific research is in finding innovative solutions for the effective care of infected people. Since its creation, Oncopole has made it a point of honor to support federative and innovative research projects in the oncology ecosystem that respond concretely to patients’ needs.
The Oncopole team has been following Dr. Perreault’s research work for the past 2 years, and is enthusiastic about the major advances that hold out real hope for the development of a therapeutic cancer vaccine. This reinforces Oncopole’s ambition to pursue its mission of federating stakeholders in support of oncology research and innovation, with the ultimate aim of bringing benefits to patients. |
